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1. Introduction
All conditions causing pulmonary hypertension (PH) are characterized by three major changes
in the pulmonary vasculature: vasoconstriction, vascular remodeling, and thrombosis [1,2,3].
Vascular remodeling includes muscularization of normally non-muscular peripheral pulmo‐
nary arteries, increase in medial wall thickness of muscular arteries, and increase in vascular
connective tissue such as collagen and elastin [1,2,3]. Imbalance of vasoconstrictive and
vasodilatory mediators might explain the increased vascular tone [1,2,3]. Endothelial cells
synthesize and release prostacylin and nitric oxide for vasodilation as well as endothelin and
thromboxane for vasoconstriction. Approved treatments for pulmonary arterial hypertension
(PAH) include prostacyclins, endothelin receptor blockers, and phosphodiesterase-5 inhibitors
as well as inhaled NO for persistent pulmonary hypertension of the neonate (PPHN) [2].
Studies have demonstrated that short- and long-term NO inhalation improves arterial
oxygenation and reduces pulmonary artery (PA) pressure in animal models of PH
[4,5,6,7,8,9,10] and clinical disease such as post-operative congenital heart disease [11,12],
chronic obstructive pulmonary disease (COPD) [13], pulmonary fibrosis [14], and acute
respiratory distress syndrome (ARDS) [15]. In chronic hypoxia-induced PH in rats, we showed
that low-dose NO (less than 5ppm) induces a submaximal reduction in pulmonary artery
pressure, which does not correlate with the severity of pulmonary vascular changes [4].
Clinically, the effect of inhaled NO is based on pulmonary vasorelaxation. In experimental
settings, NO inhibits vascular smooth muscle cell proliferation directly through regulating
protein kinases modulating gene expression for cell growth and/or indirectly through reducing
pressure on the vascular cells by cyclic guanosine-3’,5’-monophosphate (cGMP) dependent
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vascular relaxation. In this chapter we will discuss NO and its regulation and function with
special references to the development of PH as well as pulmonary vascular reactivity in PH.
2. Biological effects of NO
2.1. NO acts through the sGC pathway and S-nitrosylation of target proteins
NO activates soluble guanylyl cyclase (sGC) stimulating cGMP production and subsequent
activation of cGMP-dependent protein kinase (PKG). This sGC-cGMP-PKG pathway plays a
major role in NO-mediated regulation. In addition to this pathway, NO directly binds to
proteins and induces conformational changes with subsequent functional alterations, like
phosphorylation. Thus, S-nitration is also called S-nitrosylation, the term which emphasizes a
biological effect of the chemical reaction of S-nitration [16]. S-nitrosylation modifies the activity
of some kinases and phosphatases, thus raising the possibility that NO modifies phosphory‐
lation and dephosphorylation through S-nitrosylation.
NO reacts with oxygen, transitional metal ions, thiols, and superoxides, exerting its effects via
cGMP-dependent and/or -independent pathways. cGMP effector molecules include cGMP-
dependent protein kinases type-I and –II, cGMP-activated phosphodiesterases, and cGMP-
gated ion channels. Similar to phosphorylation, S-nitrosylation regulates protein function
allosterically or by direct modification of cysteine.
In the vascular system, NO reacts with sGC forming cGMP, which activates cGMP-dependent
protein kinase decreasing vascular smooth muscle cell cytoplasmic Ca2+ concentration by 1)
activation of proteins such as Ca2+-sensitive potassium channels which decrease membrane
potential thereby causing hyperpolarization and closing voltage dependent Ca2+ channels; 2)
phosphorylation of voltage- and receptor-operated sarcolemmal Ca2+ channels, causing them
to close; 3) inhibition of the inositol 1,3,5-trisphospate-sensitive Ca2+ release channel of the
sarcoplasmic reticulum [17].
2.2. NO prevents the development of PH
NO mediates vasorelaxation, anticoagulation, and anti-proliferation, as well as neurotrans‐
mission. Several earlier studies demonstrated that NO inhibits smooth muscle cell growth by
a cGMP-dependent mechanism [18] in addition to inhibiting growth regulating enzymes such
as ribonucleotide reductase and thymidine kinase [19,20]. NO also suppresses the hypoxia-
induced increase in ET-1 and platelet-derived growth factor-B, both of which have vasocon‐
striction and growth effects [21]. These effects of NO led investigators to determine whether
administration of NO prevents the development of PH. Chronic NO inhalation ameliorates
the development of hypertensive pulmonary vascular changes of chronic hypoxia-induced PH
in rats [22], but not in monocrotaline (MCT)-induced PH [23]. In contrast, supplementation
with the NO precursor, L-arginine, but not D-arginine prevented the development of PH in
both models [24]. The reason for the different effects of NO inhalation is unclear, but may be
a result of differing pathogenic mechanisms in the two models of PH: the increase in pulmo‐
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nary pressures precedes the vascular structural changes in chronic hypoxia-induced PH,
whereas the reverse sequence of events occurs in MCT-induced PH. Endogenous NO from L-
arginine could prevent the development of new muscularization of peripheral pulmonary
arteries in both models, whereas exogenous inhaled NO would be effective only in hypoxia-
induced PH because of the reduction in pulmonary vascular pressures caused by NO mediated
vasodilation.
Inhaled NO likely attenuates the hypertensive vascular structural changes through pulmonary
vasodilation by a cGMP-mediated mechanism. Endogenous NO from L-arginine might also
prevent the development of structural changes through a cGMP-mediated mechanism. This
hypothesis is supported by another study that showed that pulmonary gene transfection of
atrial natriuretic peptide (ANP), another inducer of cGMP, attenuates the development of
chronic hypoxia-induced pulmonary vascular changes [25]. Treatment to increase NO
production in the pulmonary vascular bed by eNOS gene transfection ameliorates the
development of PH. Studies have demonstrated that eNOS transfected smooth muscle cell
administration prevented the development of MCT-induced PH [26] and that eNOS trans‐
fected bone marrow-derived endothelial-like progenitor cell venous administration reversed
established MCT-induced PH [27].
3. Endogenous NO production
3.1. Nitrate (NO3-) and nitrite (NO2-) as sources of NO (Figure 1)
NO is produced from L-arginine by nitric oxide synthase (NOS) in the presence of oxygen,
tetrahydrobiopterin (BH4), and reduced NADPH[3]. Recent studies have indicated that
inorganic anions, nitrate (NO3-) and nitrite (NO2-), can be recycled to NO in vivo as alternative
sources of NO in addition to the classical NOS-NO pathway. The source of nitrate includes the
endogenous NOS-NO synthase pathway and the diet. Green vegetables such as lettuce and
spinach provide nitrate and preservatives in cured meat and bacon include nitrite. Basically
reduction of nitrate and nitrite produce NO, thus nitrate and nitrite are considered an ‘endo‐
crine reservoir’ of NO [28].
Nitrate in the plasma is excreted into the saliva, whereas nitrate is reduced by the oral anerobic
bacteria producing nitrite. These bacteria use nitrate as an electron acceptor instead of oxygen
during respiration. During its subsequent movement into the stomach, nitrite undergoes
further reduction to NO, thus leading to gastric NO formation, which may play a role in gastric
mucosa maintenance. This is a entro-salivary circulation of nitrate. In the systemic circulation
intravascular nitrite is reduced to NO by deoxyHb, respiratory chain enzymes, xanthine
oxidoreductase, deoxygenated myoglobin, and protons ( 29 ). They facilitate the transfer of
protons to NO2-, causing NO production which is intensified under acidic and hypoxic states.
Artery-to-vein gradients in nitrite are observed.
Nitrite has a vasodilatory effect. Inhaled nebulized sodium nitrite reduces pulmonary artery
pressure (PAP) without changes in systemic artery pressure in hypoxia- or thromboxane-
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induced PH [30]. Intravenous administration of sodium nitrite reverses PH induced by
hypoxia or thromboxane analogs [31]. Furthermore, intermittent nebulization of sodium nitrite
ameliorated the muscularization and hyperplasia of small pulmonary arteries, the develop‐
ment of right ventricular hypertrophy, and the rise in right ventricular pressure in chronic
hypoxia- or MCT-induced PH in rats [32], which is similar to L-arginine administration[33].
The effects of inhaled NO are not restricted to the lung. Recent studies have shown that inhaled
NO improves neurological and left ventricular dysfunction after successful cardiopulmonary
resuscitation [34] as well as liver function after liver transplantation [35]. Inhaled NO is
converted to nitrate and nitrite when it enters the blood [36, 37]. NO can be recycled from
nitrite and be used to protect organs from ischemia reperfusion injury.
Figure 1. Recycling of NO from NO2- Endogenous NO includes NO produced from L-arginine by NOS and recycled NO
from NO2-. NO is converted to NO3- by the reaction with the Hb and /or to NO2- by the oxidation in the plasma with the
aid of multicopper oxidase and NO oxidase ceruloplasmin. NO3- is excreted into urine by kidney and/or into oral cavity
by salivary gland. In the oral cavity anaerobic bacteria reduces NO3- converting to NO2-, which goes down into stomach
and is protonated under the gastric acidic state forming nitrous acid (HNO2) with further decomposition to NO and/or
other nitrogen oxides. NO2- in the plasma is reduced and converted to NO by the reductase activity of deoxygenated
hemoglobin, xanthine oxidoreductase, respiratory chain enzymes, and hydrogen ion. Hb(FeII), deoxygenated hemo‐
globin;Hb(FeII)O2, oxygenated hemoglobin; NO, nitric oxide; NOHb(FeII), nitrosylhemoglobin; NOS, nitric oxide syn‐
thase; NO2-, nitrite, NO3-, nitrate; XOR, xanthine oxidoreductase; Hb(FeIII), methemoglobin; REC, respiratory chain
enzymes
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Figure 2. Coupled eNOS (eNOS homodimer) produces NO. (a) eNOS homodimer produces NO, whereas eNOS
monomer produces superoxide. eNOS uncoupling occurs during the conversion of eNOS homodimer to eNOS mono‐
mer. Two eNOS monomers are connected with the aid of Zn2+, making eNOS homodimer. BH4 strengthen the Zn2+
connection, maintaining the dimer form. In coupled NOS, an electron is transferred to L-arginine, producing NO and L-
citrulline. (b) electron(+) from NADPH is transferred to O2 in the uncoupled eNOS in absence of BH4(b-1) and/or L-
arginine(b-2), thereby producing superoxide. BH4, tetrahydrobiopterin; eNOS, endothelial nitric oxide synthase; F,
flavin; NADPH, nicotinamide adenine dinucleotide phosphate
3.2. NOS uncoupling: NOS produces NO and superoxide depending on whether it is a
homodimer or monomer (Figure2)
In the process of NO formation from oxygen and L-arginine, oxygen molecules are incorpo‐
rated in both NO and L-citrulline, showing that NOS is a dioxygenase [38]. NOS containes
both a reductase domain and an oxygenase domain, where electron transfer occurs from the
reductase domain to the oxygenase domain. NADPH and flavin bind to the reductase domain,
while oxygen, BH4 and L-arginine bind to the oxgenase domain. Electrons are transferred from
NADPH through the flavin containing reductase domain to the oxygenase domain [39]. Then
two cascades of further electron transfer occur depending on the presence or absence of BH4
and L-arginine. When both BH4 and L-arginine are present, NO is synthesized by oxidative
deamination of arginine by NOS, where the electron is transferred to L-arginine. The initial
step of L-arginine oxidation is donation of electrons to the ferrous–dioxygen complex from
BH4, where trihydrobiopterin is produced and the electron is supplied through flavin
regaining BH4 [40]. In contrast, in the absence of L-arginine or BH4, NOS synthesizes the
superoxide, where the electron is transferred to ferrous oxygen. Intracellular deficiency of BH4
induces superoxide generation from eNOS [40]. The term “eNOS uncoupling” means func‐
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tionally that electron transfer to L-arginine is uncoupled, when the electron is transferred to
ferrous-dioxygen instead of L-arginine, producing superoxide. NOS homodimer produces NO
from L-arginine and oxygen, whereas NOS monomer produces superoxide [41]. Thus, the
molecular basis of eNOS uncoupling is conversion of the NOS dimer to the NOS monomer.
To maintain the NOS dimer, BH4 is essential and dihydrobiopterin (BH2) is the oxidized form
of BH4. Peroxinitrite oxidizes BH4 to BH2, reducing the BH4 amount and/or the BH2/BH4
ratio, both of which induce eNOS uncoupling [42]. The effects of BH4 are mediated through
the regulation of NO compared with superoxide synthesis by endothelial NOS. Since BH4
might both augment NO synthesis and decrease superoxide production, BH4 deficiency may
play a role in the pathogenesis of PH.
eNOS uncoupling is evaluated by the eNOS dimer/monomer ratio in cold SDS-PAGE Western
blot analysis. While oxidative stress reduces the eNOS dimer/monomer ratio in a cardiac
hypertrophic model suggesting eNOS uncoupling, exogenous BH4 restored the eNOS dimer/
monomer ratio [43]. Administration of exogenous BH4 might be used for eNOS uncoupling
diseases. BH4 deficiency might cause PH in mice and BH4 augmentation might ameliorate the
development of PH. Mice with low BH4 tissue levels develop PH which is reversed by
increasing BH4 with targeted transgenic overexpression of the rate-limiting enzyme in BH4
synthesis, guanosine triphosphate(GTP) cyclohydrolase [44]. Lung BH4 availability is con‐
trolled by pulmonary vascular tone, right ventricular hypertrophy, and vascular structural
remodeling. BH4 is a cofactor of NOS in the production of NO. BH4 deficiency causes
decreased NO production with concomitant production of superoxide by NOS. Chronic
administration of BH4 analogues improves NO-mediated pulmonary artery dilatation in rats
with chronic hypoxic pulmonary hypertension [45]. Copresence of increased levels of NOS
and reduced NO bioactivity might be explained by the deficiency of BH4 and/or L-arginine.
Long-term increases in NO might increase eNOS expression and eNOS uncoupling, thereby
producing superoxide. Long-term administration of nitroglycerin (TNG) increased eNOS
mRNA and protein expression and vascular superoxide (O2•- ) in intact vessels monitored
using ESR spectroscopy [46]. An earlier study showed that endothelial denudation improves
vascular relaxation induced by TNG in isolated vessels from nitrate-tolerant animals [47].
3.3. Caveolin and NOS (Figure 3)
Caveolae are flask-shaped invaginations on the cell surface, which contain structural proteins
called caveolin and other signaling proteins. In endothelial cells, eNOS is inactivated when it
is conjugated to caveolin-1, a structural protein of endothelial caveolae; eNOS is activated
when it dissociates from caveolae. Stimulation of β2 adrenergic receptors cause this dissocia‐
tion through phosphorylation of Tyr in caveolin-1. The mouse pulmonary endothelial β2
adrenergic receptor coupled to Gi/o proteins causes phosphorylation of caveolon-1 by Src
kinase and eNOS phosphorylation at ser1177 by the Src kinase - phosphatidylinositol 3 kinase
(PI3kinase) - Akt kinase pathway [48]. Thus, stimulation of the β2 adrenergic receptor causes
endothelial NO synthase-dependent relaxation.
Loss of caveolin-1 induces chronic activation of eNOS and subsequent tyrosine nitration of
PKG in lungs from patients with idiopathic pulmonary hypertension, where activated eNOS
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is uncoupled eNOS, producing superoxide [49]. Genetic deletion of caveolin in mice causes
PH and treatment with a superoxide scavenger and/or a NOS inhibitor prevents PH associated
vascular remodeling [49]. Although caveolin expression in total lung determined by Western
blotting is not altered in severe PH, its immunohistological expression in plexiform lesions is
absent or decreased [50].
A 90-kDa heat  shock protein  (HSP90)  is  a  molecular  chaperone  of  proteins  that  modu‐
lates  protein functions.  Along with many other proteins,  eNOS and sGC are targets  for
HSP90. HSP90 interacts with eNOS and HSP90 facilitates the displacement of eNOS from
caveolin 1, activating eNOS. HSP90 activity is dependent on adenosine triphosphate (ATP).
Asymmetric dimethylarginine (ADMA) inhibits HSP90 activity in pulmonary endothelial
cells through mitochondrial dysfunction, caused by ADMA induced eNOS uncoupling with
subsequent superoxide production and nitration of  mitochondrial  protein,  which reduce
ATP production [51].
3.4. eNOS expression and activity in PH
To examine whether the change in eNOS expression and its activity is associated with vascular
endothelial dysfunction in PH, many studies have been performed in several species of animals
and humans, using isolated lung, isolated pulmonary artery, and in vivo. eNOS is expressed
in not only vascular endothelial cells, but lung epithelial cells. In addition, eNOS expression
and/or activity might be different between conduit PAs and resistance PAs.
Animal models
mRNA and protein expression of eNOS in rat lung and eNOS expression localized in pulmo‐
nary vascular endothelial cells and epithelial cells is upregulated in acute hypoxia [52]. In that
study, nitrate/nitrite in rat lung homogenate also increased, suggesting augmented eNOS
activity. The enhancement of eNOS activity in hypoxic pulmonary vasoconstriction (HPV) in
normal rat lung also has been shown in other studies using NOS inhibitors [53, 54] (see sect.
3.1). eNOS protein expression was time-dependently increased in rats in chronic hypoxia-
induced PH [55,56], while phosphorylated eNOS (peNOS), active form, was impaired [55].
MCT-induced PH rats showed decreased expression of both eNOS [57,58,59] and peNOS [59].
Human
Many studies of eNOS expression and its activity have been performed in adult human PAH.
However, the results are not consistent: eNOS expression is reduced in pulmonary vessels
from adults with primary and secondary PH, but is increased in plexiform lesions [60]. Western
blot analysis showed that eNOS expression is not changed in the lung tissue of idiopathic PAH
(IPAH) patients [61]. However, several studies reported lower exhaled nitrate/nitrite (NOx) in
PAH patients [62,63]. Overall, these results suggest that eNOS activity might be depressed in
adult human PAH.
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4. Endothelium-dependent and -independent NO-mediated relaxation in
pulmonary circulation
4.1. Role of endothelium-derived NO in basal tone
L-NMMA (N omega-monomethyl–L-arginine), L-NNA (N omega-nitro-L-arginine), L-NAME
(N omega-nitro-L-arginine methyl ester), L-NA(N omega-nitro-L-arginine) and other NOS
inhibitors have been used to examine the physiological role of NO in pulmonary vascular tone.
The increase in vascular tone in the presence of NOS inhibitors may indirectly represent NO
production and/or release in the pulmonary circulation.
Animals
L-NMMA [53] and L-NNA [64,65] did not change pulmonary basal tone in normal rat PA rings.
Normal isolated perfused lungs were not affected by NOS inhibitors such as L-NMMA [53],
L-NNA [64], and L-NA [66] except for a few studies showing a moderate increase with L-
NAME [67]. In chronic hypoxia, many studies showed markedly enhanced vascular tone by
L-NNA [64] or L-NAME [67]. Although these NOS inhibitors caused different results, the
findings suggested that 1) NO might not be involved in vascular basal tone in normal pulmo‐
nary circulation, and 2) basal NO production might be increased in hypoxia-induced chronic
Figure 3. Inactive form of eNOS associated with caveola. eNOS is associated with caveola, which is the inactive
form of eNOS. The active form of eNOS is dissociated from caveola. Stimulation of BMPIIR induces dissociation of
eNOS from caveola as well as phosphorylation of eNOS through PKA and/or Akt activation. eNOS, endothelial nitric
oxide synthase; B2-AR, beta 2-adrenergic receptor; SrcK, src kinase; peNOS, phosphorylated eNOS; BMPIIR, bone mor‐
phogenetic ptotein II receptor; PKA, cyclic AMP-dependent protein kinase
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PH. On exposure to acute hypoxia, NOS inhibitors augmented vascular contraction in normal
[53,67,68] and hypoxia-induced PH rat models [67]. This finding suggests that NO production
in HPV is increased in both normal and hypoxic PH rats.
Humans
Inhibition of NO production by L-NMMA caused the reduction of pulmonary flow in
conscious healthy adults [69,70], suggesting the possible role of continuous production of NO
in maintaining basal vascular tone. In PAH patients, several studies reported decreased
expression of NOS. Although several studies reported decreased exhaled nitrogen oxide (NOx)
levels in PAH patients, others have reported higher levels. The results therefore remain
inconclusive.
4.2. Vasoreactivity to endothelium-dependent and independent NO-related relaxing
substances in rat lung
Many studies have been performed using acetylcholine (Ach) and sodium nitroprusside
(SNP), endothelium-dependent and -independent NO-related vasorelaxants, to examine
functional changes in vascular endothelial and smooth muscle cells in PH. As Ach-induced
relaxation was abolished by NOS inhibitors [64] and restored with L-arginine [71,72], reactivity
may partly reflect changes in NOS expression and/or activity.
Rats with hypoxic PH
The relaxation response to Ach is impaired in rat isolated conduit pulmonary arteries (PAs)
[65,73,74,75,76]. Many of these studies also described an impaired relaxation response to SNP
in conduit PAs [65,74,76]. These results suggested 1) decreased production and release of NO
in endothelial cells or 2) decreased responsiveness to NO in smooth muscle cells, or both.
Impaired relaxation in Ach and SNP was partially restored after exposure to chronic hypoxia.
As the recovery process was different between the responses of Ach and SNP [65], it was
speculated that NO-related functional abnormalities in endothelial and smooth muscle cells
occurred independently.
In contrast, in hypoxic vasoconstriction resistant rat PA rings, the relaxation response to Ach
was not changed [74,75] or augmented [77] in chronic hypoxia. It is likely that Ach-reactive
NO production and/or release varies in a vascular site-specific manner. Conduit arteries
produce and release more eNOS than peripheral arteries. The vascular functional change in
response to stimuli such as abnormal shear stress, circumferential wall stretch and hypoxia
itself may occur in conduit PAs more than in peripheral resistant arteries. Although conduit
arteries do not directly relate to pulmonary vascular resistance, the pathophysiological change
in conduit arteries may play a key role in pulmonary vascular remodeling [78].
Impaired response to Ach was partly restored in the presence of a non-selective inhibitor of
cyclooxygenase (COX) [65] or prostaglandin (PG) H2 / thromboxane (TX) A2 receptor antago‐
nist [79], suggesting the possibility of 1) imbalance between the production of vasocontracting
and vasorelaxing prostanoid in vascular endothelial cells, and 2) simultaneously release of
vasocontracting prostanoids such as PGH2 and/or TXA2. Pidgeon et al. showed that the basal
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expression of COX2, otherwise known as PGH synthase, was increased in rat lungs in chronic
hypoxia, and a PGH2/TXA2 receptor antagonist attenuated the rise in PAP induced by chronic
hypoxia [80].
MCT-induced PH in rats
PA vascular functional changes in rats with MCT-induced PH have been compared with PAs
from animals with chronic hypoxia-induced PH. Many vasodilation studies have reported a
depressed relaxation response to Ach in MCT-induced rat conduit PA rings [76,81,82,83,84].
Many of these studies described impaired SNP relaxation, [76,82] with the exception of one
study [84]. While Ach-induced relaxation was impaired in the pulmonary circulation in MCT-
induced PH, the SNP relaxation response has been reported to be impaired [85] or not impaired
[86]. Taken together, in MCT-induced PH, vascular endothelial dysfunction is observed from
proximal to distal PAs; however, smooth muscle functional alteration is not apparent in
peripheral PAs.
5. Superoxide scavenges NO producing peroxynitrite (Figure 4)
5.1. Oxidative stress
In pulmonary hypertension, endothelial NOS expression is increased, which may not neces‐
sarily indicate an increase in NO production [87]. NOS might produce superoxide, which is
due to uncoupling of NOS [88]. Increased levels of NOS and reduced NO bioactivity might be
explained by the deficiency of BH4 and/or L-arginine. Oxidative stress induces the changes of
BH4 to BH2. Oxidative stress also induces S-glutathionylation and subsequent eNOS uncou‐
pling [39], in which S-glutathionylation of eNOS reversibly decreases NOS activity with an
increase in O2•- generation primarily from the reductase and endothelium-dependent relaxa‐
tion is impaired. Oxidative stress upregulates nuclear factor (NF)-kappaB, a key transcription
factor that is involved in vascular tissue remodeling. NF-kappaB nuclear localization and
vascular cell adhesion molecule 1(VCAM-1) expression is temporally and spatially associated
with the development of MCT-induced PH in rats, which is ameliorated by administering a
NF-kappaB inhibitor, pyrrolidine dithiocarbamate(PDTC)[89].
5.2. Production of superoxide in PH: role of NADPH oxidase and SOD
NAD(P)H oxidase enzyme complex catalyzes one electron reduction of oxygen using NADPH
or NADH as an electron donor, which produces superoxide : NAD(P)H + 2O2 → NAD(P) + +
H+ +2O2-‘ NADPH oxidase expression is increased in pulmonary arteries from a lamb model
of persistent pulmonary hypertension of the newborn (PPHN) [90]. The expression was
determined by the Western blotting of the levels of p67phox a subunit of the NADPH oxidase
complex and immunostaining of the pulmonary vessels in lung sections. Another study
demonstrated that expression and activity of the NADPH oxidase complex are upregulated
in PH with increased pulmonary blood flow [91].
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Deficiency of superoxide dismutase (SOD) may play a role in the development of PH.
Expression and activity of mitochondrial SOD2 in patients and animal models of PH is
decreased [92,93] in pulmonary arteries and plexiform lesions. SOD produces H2O2 from
mitochondrial superoxide. H2O2 is less potent than superoxide and acts as a signaling molecule
to inhibit transcriptional factors such as hypoxia-inducible factor-1α. Epigenetic suppression
of SOD with selective hypermethylation of CpG islands in SOD2 gene induces excessive
proliferation and decreases apoptosis in pulmonary artery smooth muscle cells [92], suggest‐
ing a causative role of SOD deficiency in PH.
NO reacts with superoxide more rapidly than SOD producing peroxinitrite. Peroxynitrite is a
more potent and versatile oxidant than NO or superoxide, in which HO+ and NO2 produced
from peroxynitrous acid (HOONO) and/or its reactive activated isomer (HOONO*) attacks
biological targets [94] including cyclic GMP-dependent protein kinase (PKG). In the setting of
eNOS uncoupling, eNOS synthesizes superoxide which reacts with NO to create peroxynitrite.
Nitrosylation of PKG by ONOO- depresses the function of PKG ( 42 ).
Figure 4. Peroxynitrite production from NO and superoxide. Superoxide (O2.-) is produced by uncoupled eNOS,
NADPH oxidase, and xanthine oxidase. NO reacts with O2.- producing peroxynitrite(ONOO-) with subsequent nitrosyla‐
tion of protein kinases, thereby activating or suppressing their activities. PKG phosphorylates Rho kinase, Akt, and ion
channels. Phosphorylation of ion channels makes Ca2+ ion channels closed and potassium channel open. Peroxynitrite
further oxidize BH4 to BH2, inducing eNOS uncoupling with subsequent superoxide production. BH4, tetrahydrobiop‐
terin; BH2, dihydrobiopterin; eNOS, endothelial nitric oxide synthase; ERK, extracellular signal-regulated kinase; IP3,
inositol triphosphate receptor; MAPK, mitogen-activated protein kinase; OX, oxidase; ONOO-, peroxynitrite; PKC, pro‐
tein kinase C; PKG, cyclic-GMP dependent protein kinase( protein kinase G); XOX, xanthine oxidase;
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6. Prevention of hypertensive pulmonary vascular remodeling through
NOS/NO pathway
6.1. NO precursor L-arginine ameliorates PH
Arginase, an enzyme in the urea cycle, converts arginine to ornithine and urea. NOx concen‐
trations in exhaled gas and serum are decreased in PH patients compared with normal persons
[95], suggesting decreased NO availability in PH. The deficiency of the NO precursor L-
arginine, the substrate depletion of NOS, might partly explain the decrease in NO availability.
Lower levels of arginine in the cell might be due to the increased activity of arginase. In PH
patients, lower levels of arginine correlate with higher pulmonary artery pressures. Serum
arginase activity is higher and the serum arginine-ornithine ratio is lower in PH patients than
in healthy controls, indirectly suggesting increased intracellular arginase activity [33]. Animal
studies showed that prolonged administration of L-arginine ameliorated the development of
monocrotaine-induced PH [24,96] and chronic hypoxia-induced PH [96]. In patients with PH
L-arginine treatment reduces PAP [97]. In addition to functioning as the substrate for NO
formation, L-arginine prevents eNOS uncoupling, serves as a direct radical scavenger, and
competes with the endogenous eNOS inhibitor ADMA, which decreases superoxide and
increases NO formation [41].
6.2. ATRA increases NO production (Figure 5)
The level of asymmetrical dimethylarginine (ADMA) is increased in patients with PAH and
MCT-induced PH in rats [98]. Since ADMA is an endogenous competitive inhibitor of NOS
and suppresses NOS activity, increases in ADMA inhibit NO production. In atherosclerotic
arteries from patients with high serum ADMA, endothelium-dependent relaxation by
acetylcholine was impaired and O2•- production was increased [99]. Dysregulation of ADMA
might cause PH through the decrease in NO in the lung as well. Dimethylarginine dimethya‐
minohydrolase (DDAH) is a metabolizing enzyme of ADMA. Thus the increase in DDAH
activity reduces ADMA and induces subsequent increases in NOS activity. DDAH has two
isoforms: DDAH 1 and DDAH 2. DDHA 1 and DDAH 2 are expressed predominantly in tissues
containing neuronal NOS (nNOS) and eNOS, respectively [100]. Phosphodiesterase (PDE) 3/4
inhibitors reduce ADMA and raise NO/cGMP levels [2]; PDE3/4 inhibitors activate the cAMP/
protein kinase A (PKA) pathway and induce subsequent activation of the promoter region of
DDAH2. Western blot analysis of lung from PH rats 28 days after the injection of MCT showed
decreases in eNOS, pNOS, AKT, and DDAH2 and increases in lung and serum ADMA levels
[101]. In this PH model, 1) decreased Akt reduces eNOS phosphorylation and thereby
decreases eNOS activity 2) decreased DDAH2 reduces ADMA breakdown and thereby the
increase in ADMA inhibits eNOS activity. This study showed that rosuvastatin ameliorates
MCT-induced PH through the normalization of Akt, eNOS and DDAH2 expression and
ADMA levels [101].
Endothelial cells express retinoid receptors and all-trans-retinoic acid (ATRA) increased
DDHA2 mRNA levels in endothelial cells. Although eNOS mRNA expression is not increased
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with ATRA treatment, ATRA increases NO production, suggesting that ATRA increases
activity of expressed eNOS indirectly through the decrease in ADMA due to increased DDHA2
[102]. ATRA also upregulates NO production in vascular endothelial cells through the PI3
kinase/Akt pathway [103]. ATRA induces eNOS phosphorylation at ser1177 and Akt phosphor‐
ylation at ser473 without changes in protein expression such as occur during DDAH2 upregu‐
lation. In terms of inducible NOS(iNOS), interleukin(IL)-1β increases iNOS mRNA levels and
ATRA reduces this increase in vascular smooth muscle cell culture [104]. Because iNOS
inhibition by the iNOS inhibitor N6-(1-iminoethyl-L-lysine, dihydrochloride(L-NIL) prevent‐
ed the development of PH [105], the inhibitory effect of ATRA on iNOS expression might
reduce the development of PH. Peroxisome proliferator-activated receptors (PPARγs) are a
nuclear hormone receptor superfamily of ligand-activated transcription factors of retinoid
hormone receptors other than steroid and thyroid hormones. PPARγ or retinoid X receptor
(RXR) agonists inhibit smooth muscle proliferation. The PPARγ agonist rosiglitazone attenu‐
ates the development of chronic hypoxia-induced vascular structural remodeling [106],
although it has little effect on the vasoconstriction component of PH. Since PPARγ mediates
effects through the RXR, retinoids might also ameliorate PH vascular changes. PPARγ ligands
increase the release of NO from endothelial cells through a transcriptional mechanism
probably through the increase in DDAH mRNA expression without changes in eNOS
expression [107]. These results suggest that ATRA might prevent the development of experi‐
mental PH in rats. ATRA ameliorated the development of MCT-induced PH [108], but not
chronic hypoxia-induced PH [109]. These differences in the effect of ATRA on the development
of PH may be due to a more pronounced inflammatory response in MCT-induced PH and a
more subtle inflammatory reaction in chronic hypoxia-induced PH; endothelial damage
precedes the rise in PAP in MCT model whereas the rise in PAP precedes endothelial changes
in the chronic hypoxic model [110,111].
6.3. BMPIIR activates eNOS
Mutation of the bone morphogenetic protein receptor type II (BMPIIR) gene is one of the causes
of familial PAH. The link between BMPIIR and eNOS partly explains the mechanism for the
development of PH caused by BMPIIR mutations. Stimulation of BMPIIR induces eNOS
phosphorylation, primarily through the cyclic-AMP dependent protein kinase and partially
through serine-threonine kinase Akt [112]. Stimulation of BMPIIR also causes dissociation of
eNOS from caveolin-1 and increases the eNOS-HSP90 interaction, which facilitates electron
transfer through eNOS[112]. Thus, impaired BMPIIR or loss of BMPIIR stimulation might
disturb the pulmonary vascular homeostasis, thereby causing PH.
6.4. VEGF increases eNOS expression
Vascular endothelial growth factor (VEGF) stimulates NO production initially by increasing
intracellular Ca++ levels and subsequent Ca++-calmodulin dependent activation of eNOS, and
later by increasing intracellular eNOS message and protein levels [113]. VEGF stimulates
vasodilation, microvascular hyperpermeability, and angiogenesis. Plexiform lesions show
striking expression of VEGF associated with endothelial proliferation. NOS inhibition prevents
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VEGF-induced proliferation in cultured microvascular endothelial cells, associated with the
decrease in cGMP levels [114], suggesting that VEGF-induced proliferation is in part mediated
by the NOS-NO-cGMP pathway. VEGF induces translocation of eNOS and caveolin-1 from
caveola to the nucleus, where NO production activates transcriptional factors thereby inducing
the early growth response gene, c-fos [115] and possibly inducing angiogenesis, and endothe‐
lial cell growth. VEGF receptor 2 (VEGF2R) blockade combined with chronic hypoxic exposure
causes PH with plexiform like lesions, where decreased expression of VEGF2R, Src, Akt,
phosphorylated Akt protein in lung have been demonstrated [116]. Studies have demonstrated
that reduced Src and Akt attenuate eNOS phosphorylation [101].
Figure 5. Possible pathway to enhance NO production by ATRA, DDAH, PDE3/4 inhibition, and BMPIIR. ADMA
supresses NOS activity. DDAH is the enzyme that metabolizes ADMA. The cAMP/PKA pathway activates the promoter
region of DDAH2, thereby increasing DDAH2 expression. ATRA increases DDAH2 mRNA, stimulates RAR with a subse‐
quent increase in PI3K activity as well as PI3K protein and mRNA expression, and thereby enhances Akt and eNOS
phosphorylation without increasing eNOS expression. Phosphorylated Akt(pAkt) phosphorylates eNOS making pe‐
NOS, the activated form of NOS. B2-AR stimulation activates SrcK via Gi/o protein. Activated SrcK phosphorylates PI3K
and induces subsequent its downstream eNOS phosphorylation as well as phosphorylation of caveolin -1 to dissociate
eNOS from caveola (Figure 3]. ADMA, asymmetric dimethylarginine; ATRA, all trans retinoic acid; B2-AR, beta 2-adre‐
nergic receptor; BMPIIR, bone morphogenetic ptotein II receptor; CREB, cAMP responsive element binding protein;
cAMP, cyclic adenosine monophosphate; DDAH, dimethylarginine dimethylaminohydrolase; eNOS, endothelial nitric
oxide synthase; peNOS, phosphorylated eNOS; ERK, extracellular signal-regulated kinase; pERK, phosphorylated ERK;
Gi/o, GTP binding protein subunit Gi/o; PDE, phosphodiesteras; PI3K, phosphoinositide 3-kinase; PKA, cAMP depend‐
ent protein kinase; PKG, cyclic GMP-dependent protein kinase ; PPARγ, peroxisome proliferator-activated receptor;
Srck, src kinase; RAR, retinoic acid receptor;
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6.5. Elastase inhibition by NO
Earlier studies have shown that vascular elastase activity is increased in MCT-induced PH and
chronic hypoxia-induced PH in rats [3,117], and that elastase inhibition prevents the develop‐
ment of pulmonary hypertension, right ventricular hypertrophy, muscularization of periph‐
eral pulmonary arteries and medial hypertrophy of muscular arteries [3,117,118]. NO might
reduce the elastase activity through its scavenging effect of superoxide. Reactive oxygen
species inactivates endogenous elastase inhibitor, α1-protease inhibitor, and might increase
elastase activity [119]. Furthermore NO might reduce elastase expression by inhibiting its
transcriptional factor, acute myeloid leukemia factor 1 (AML-1), through extracellular signal-
regulated kinase mitogen-activated protein kinase (ERK MAPK) inhibition which is mediated
by cGMP dependent protein kinase activation [120].
Figure 6. Rho/Rho kinase pathway inhibits eNOS/NO/cGMP pathway Rho kinase is activated by the guanosine
triphosphate (GTP)-bound, active form of RhoA (GTP RhoA). Activated Rho kinase phosphorylates and subsequently
inactivates myosin phosphatase, causing smooth muscle contraction, which is the RhoA/Rho kinase pathway. PKG
phosphorylates Rho A at Ser188 and inhibits Rho A function, thereby inactivating the RhoA/Rho kinase pathway. Acti‐
vated RhoA/Rho kinase decreases eNOS mRNA and protein expression, inactivates Akt, and inhibits PKG activity,
thereby supressing the eNOS/ NO/cGMP pathway. VEGF upregulates eNOS mRNA and protein expression. AML-1,
acute myeloid leukemia factor 1(transcriptional factor); EVE, endogenous vascular elastase; PKG, cyclic GMP-depend‐
ent protein kinase(G kinase); PKB, protein kinase B(=Akt), AML-1, acute myeloid leukemia factor 1; ML, myosin light
chain; pML, phosphorylated myosin light chain; MLCK, myosin light chain kinase; ERK MAPK, extracellular signal-regu‐
lated kinase mitogen activated protein kinase; VEGF, vascular endothelial growth factor.
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6.6. Rho-kinase inhibitor upregulates NOS in PH (Figure 6)
Myosin light chain (MLC) phosphorylation by myosin light chain kinase (MLCK) causes
vascular smooth muscle contraction. In contrast, myosin light chain dephosphorylation by
myosin light chain phosphatase causes relaxation. The phosphorylation status of MLC
phosphatase determines the contractility of smooth muscle at the same Ca++ concentration,
thereby regulating the Ca++ sensitivity for contraction; the stronger the phosphatase activity,
the weaker the vascular tone at the same Ca++ concentration. RhoA/Rho-kinase activation
augments the phosphorylation of MLC phosphatase, which results in inhibition of MLC
phosphatase. Studies have shown that Rho-kinase in circulating neutrophils is increased in
patients with PH and that Rho-kinase expression is upregulated in isolated lung tissue on
transplantation [121]. Rho-kinase activity in pulmonary arteries is enhanced in experimental
PH [122,123]. NO-cGMP-cGMP dependent protein kinase pathway suppresses Rho/Rho
kinase activity [124]. On the other hand Rho/Rho-kinase activation downregulates eNOS
expression and eNOS phosphorylation through the inhibition of the protein kinase B/Akt
pathway [125].
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